Lesch-Nyhan disease (LND) is a rare X-linked genetic disorder, with complete hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency, uric acid (UA), hypoxanthine and xanthine accumulation, and a devastating neurologic syndrome. UA excess, causing renal failure, is commonly decreased by xanthine oxidoreductase (XOR) inhibitors, such as allopurinol, yielding a xanthine and hypoxanthine increase. Xanthine accumulation may result in renal stones, while hypoxanthine excess seems involved in the neurological disorder. Inhibition of purine nucleoside phosphorylase (PNP) represents a different strategy for lowering urate. PNP catalyzes the cleavage of purine ribo-and d-ribo-nucleosides into ribose/-deoxyribose phosphate and free bases, starting catabolism to uric acid. Clinical trials demonstrated that PNP inhibitors, initially developed as anticancer drugs, lowered UA in some gouty patients, in association or not with allopurinol. The present study tested the reliability of an analogue of immucillin-G (C1a), a PNP inhibitor, as a therapy for urate, hypoxanthine, and xanthine excess in LND patients by blocking hypoxanthine production upstream. The therapeutic aim is to limit the administration of XOR inhibitors to LND patients by supplying the PNP inhibitor in low doses, avoiding d-nucleoside toxicity. We report studies conducted in primary cultures of skin fibroblasts from controls and LND patients grown in the presence of the PNP inhibitor. Cell viability, oxypurine release in culture medium, and endocellular nucleotide pattern have been monitored in different growth conditions (inhibitor concentration, time, added inosine). Our results demonstrate effective PNP inhibition by low inhibitor concentration, with reduced hypoxanthine release, and no appreciable toxicity in control or patient cells, suggesting a new therapeutic strategy for LND hyperuricemia.
| INTRODUCTION
Lesch--Nyhan disease (LND) is a rare X-linked genetic disease due to hypoxanthine-guanine phosphoribosyltransferase (HGPRT, EC 2.4.2.8) deficiency, with hyperuricaemia and a peculiar severe neurological dysfunction. [1] [2] [3] Alterations in the HPRT1 gene may cause various degrees of deficiency, all resulting in marked uric acid (UA) overproduction due to oxidation of unrecycled hypoxanthine by xanthine oxido-reductase (XOR: XDH, E.C. 1.17.1.4; XO, E.C. 1.17.3.22) and increased de novo purine synthesis.
Depending on residual HGPRT activity, severe (LND full syndrome) or milder (LND variants, LNV) neurological disability occurs. [4] [5] [6] The fine connection between the neurological syndrome and HGPRT deficiency is still unclear. 7 Hyperuricemia, often leading to renal failure, is usually treated by XOR inhibitors (allopurinol, febuxostat) effectively lowering UA, but accumulating hypoxanthine and xanthine, the latter forming stones. 8, 9 Moreover, increased hypoxanthine and xanthine concentrations in LND cerebrospinal fluid have been related to the neurological manifestation. [10] [11] [12] [13] Alternative treatments based on uricolysis have been recently proposed. 14 Lowering the activity of purine nucleoside phosphorylase (PNP, E.C. 2.4.2.1) is expected to decrease hypoxanthine production while accumulating inosine, d-inosine, guanosine, and d-guanosine. The latter is potentially toxic, while lack of toxicity was described for inosine 15 and guanosine. 16 Several base, nucleoside, and nucleotide analogues inhibiting PNP have been synthesized as specific anticancer drugs, suppressing T cell proliferation by d-guanosine nucleotides accumulation. Immucillin-H (ImmH: Forodesine) and derivatives and the DADME-immucillins 17 were tested with this purpose. Compounds belonging to this family (DADMe-ImmH: BCX-4208 or Ulodesine), proposed to lower uric acid in gouty patients, underwent toxicity tests and phase II and III clinical trials. Simplified analogues of DADMe-ImmG (SA-DADMeImmG), displaying similar PNP inhibition kinetics, were then synthesized by easier, low-cost procedures. 18 The aim of this study was to investigate the metabolic alterations occurring in HGPRT deficient cells following partial PNP inhibition by one of the above analogues, in view of a new hypouricemic therapy. Since conventional drugs increasing hypoxanthine might not help in LND, upstream hypoxanthine decrease by PNP inhibition seems an appropriate treatment, provided potential d-guanosine toxicity is prevented. To our knowledge, no preclinical study on PNP inhibitors, such as immucillin-G and derivatives, has been reported for LND.
In this study the production of hypoxanthine, xanthine, nucleosides, deoxinucleosides, and nucleotide pattern were checked in LND fibroblasts incubated with the PNP inhibitor, in order to ascertain possible metabolic damages and effective reduction of XOR substrates.
| MATERIALS AND METHODS
Reagents of analytical grade were purchased from SIGMA (St. Louis MO, USA). Other chemicals for HPLC separation were of the highest quality available.
Statistical analysis were performed by Student's t test.
| Patients and biological samples
Primary fibroblast cultures were obtained from skin biopsies of eight patients with HGPRT deficiency and different neurological presentation: six clinically diagnosed as full spectrum LND (LN1, LN2, LN3, LN4, LN6, LN8) and two with milder symptoms (LNV: LNV5 and LNV7). 19 Four healthy adult volunteers were used as controls. Blood for diagnostic purpose and enzyme activity assays was drawn by venipuncture from two LND (LN4 and LN6) and two LNV patients (LNV5 and LNV7).
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. The informed consent conformed to the standards set by the latest revision of the Declaration of Helsinki containing few substantive changes relative to the April 2013 iteration.
| Primary fibroblast isolation and culture
Fibroblasts were isolated from skin biopsies within 1 h from excision, as reported. 20 Explants were de-epidermized with dispase (14 U/ml) for 2 h at 37 C and then dissolved into collagenase III (2.4 U/ml) for 30 min. Fibroblasts were cultured in DMEM plus 10% h.i. FCS and 1% penicillin/streptomycin, at 37 C and 5% CO 2 until sub-confluence, and used for enzyme activity assay, or grown in the presence/absence of PNP inhibitor.
| Enzyme activities
Biochemical characterization of patients and controls included HGPRT, adenine phosphoribosyltransferase (APRT, E.C. 2.4.2.7), and PNP activity in fibroblast homogenates and in erythrocyte lysates, when available.
| Enzyme activities in fibroblasts and erythrocytes
Subconfluent fibroblast primary cultures were washed twice with PBS, detached by trypsinisation, harvested by centrifugation (10 min, 250 × g), and resuspended in 10 mmol/l potassium phosphate buffer, pH 7.5 (1-2 × 10 6 cells/ml).
Suspensions were freezed-thawed twice at −80 C and centrifuged (10 min, 21,000×g). Enzyme activities were assayed in clear supernatants by previously published HPLC-linked methods. 21 Protein content was measured for activity Reactions were stopped by one volume of 0.6 mol/l perchloric acid; after centrifugation (12,000 × g for 2 min) clear supernatants were brought to neutrality by K 2 CO 3 and clear supernatant used for HPLC analysis.
XOR activity was assayed in control fibroblast homogenates according to a spectrophotometric method, 22 with minor modifications. Rat liver homogenate (20% w/v in 200 mmol/l phosphate buffer, pH 7.4) was used as a positive control. Erythrocytes isolated from whole blood collected in heparin were washed twice with saline. Crude lysates were obtained by water dilution, freezed-thawed, and used for enzyme assays and hemoglobin (Hb) quantification for data normalization.
| PNP inhibitor
A 9-deazaguanosine analogue of immucillin-G, indicated as C1a (Figure 1 ), synthesized by the described procedure 18 and then dissolved in DMSO (10 mmol/l) was used to inhibit PNP. Residual PNP activity was measured in the presence of increasing inhibitor concentrations (1 nmol/l-1 μmol/l) in erythrocyte lysates and fibroblast homogenates from controls and patients; apparent kinetic parameters were measured. PNP activity was also measured adding DMSO to the assay mixture to check its potential effect (repeated five times). PNP residual activity with increasing amounts of C1a in fibroblast crude homogenates from controls (n = 4) and patients LN1, LN4, LN8, LNV5, (percent of basal activity, mean ± sd); inset: chemical structure of C1a. 18 
| Fibroblast treatment with PNP inhibitor
Inhibitor uptake by fibroblasts has been measured indirectly by measuring PNP activity in C1a treated cells (5 nmol/l -25 μmol/l) for 180 min. After treatment, cells were quickly harvested, washed with clean medium and homogenized for enzyme activity assay.
Fibroblasts from controls and patients were then treated with different concentrations of C1a (10 nmol/l -100 μmol/l) in the presence/absence of 20 μmol/l inosine, for 24, 48, and 72 h.
The MTT test 23 was performed in cell samples from all treatment conditions to check cell survival and ascertain possible toxicity. After incubation samples for HPLC analysis were prepared, medium was harvested and perchloric extract obtained by adding one volume of 0.6 mol/l HClO 4 and clarified by centrifugation. Supernatants were brought to neutrality with K 2 CO 3 and analyzed by HPLC. Cells were washed twice with clean medium; perchloric extracts were obtained by adding 0.6 mol/l HClO 4 (200 μl), cell debris were scraped and harvested suspension clarified by centrifugation (12,000×g for 2 min), brought to neutrality with K 2 CO 3, , and analyzed by HPLC. Pelleted proteins were quantified for data normalization.
| HPLC analysis
Modified HPLC-linked methods previously described 24 were used to measure nucleotide content in fibroblast extracts, nucleosides, and bases (hypoxanthine, xanthine, uric acid, inosine, guanosine, and deoxinucleosides) in medium extracts. The HPLC apparatus consisted of a Beckman System Gold Module125S, with amod.168 Nouveau diode array detector. Phenomenex Luna C18 columns (3 μm particle size, 75 × 4.6 mm) equipped with guard columns (Phenomenex Security guard 4 × 3 mm) were used. Analysis of medium extracts was performed by gradient elution using 10 mmol/l potassium phosphate, pH 5.5, and methanol as eluants. Fibroblast extracts were analyzed by gradient elution using 0.1 mol/l potassium phosphate, pH 5.5, containing 6 mmol/l tetrabutylammonium phosphate, and methanol as eluants. The HPLC procedures were performed at room temperature, with 1 ml/min flow rate, and absorbance monitoring at 260 and 280 nm. Peak identities were confirmed by retention time, coelution with added internal standards, 260/280 nm absorbance ratios, and UV/vis spectra. Quantification was based on concentration/peak area linear plots developed injecting solutions with known concentrations of each pure compound.
| In silico analysis
An in silico screening was performed focusing on the expression profiling of XDH gene in several normal human organs, tissues or cells, on the BioGPS portal (ver 9454a07) plugin "Gene expression/activity chart" using the human data sets "Barcode on normal tissues" and "Primary Cell Atlas". 25 3 | RESULTS
| Biochemical analysis of patient erythrocytes and fibroblasts
Virtually no HGPRT activity was detectable in erythrocyte lysates and fibroblast homogenates from LND patients. GPRT was measurable only in fibroblast homogenates from four patients (LNV5, LN6, LNV7, LN8) displaying from 1 to 10% residual activity (Table S1 in Appendix S1). Patients LNV5 and 7 displayed milder symptoms 19 while LN6 and 8 were diagnosed as full LND; currently there is no explanation for such findings. Patient APRT activity was twice to three times control values in erythrocytes (p < 0.01, t test analysis, Table S1 ), whereas no difference was observed in fibroblasts. Patient PNP activity was significantly higher than controls in erythrocytes (p < 0.05, t test analysis) and fibroblasts (not statistically significant) (Table S1 ).
| PNP inhibition by C1a
Concentration-dependent PNP inhibition by C1a up to 20 nmol/l was demonstrated in erythrocyte lysates from patients and controls, with IC 50 3 nmol/l ( Figure S1A ). DMSO, used to dissolve C1a, did not demonstrate any significant effect on PNP activity (2923 ± 219 nmoles/h/mgHb in the absence, 2965 ± 150 in the presence of DMSO, mean ± sd of five separate assays). Apparent kinetic constants were measured in control erythrocyte lysates in the absence and presence of C1a (1, 2 and 4 nmol/l). Apparent Km inosine was not altered (0.165 mmol/l in the presence and 0.168 in the absence of 4 nmol/l C1a), while Vmax was decreased from 3584 to 208 nmoles/h/mg Hb, which suggested a non-competitive inhibition ( Figure S2A) .
A concentration-dependent inhibition pattern was found in control and patient fibroblast homogenates (Figure 1) , with IC 50 4 nmol/l ( Figure S1B ); apparent Km inosine was 0.180 mmol/l in the absence and 0.190 in the presence of 4 nmol/l C1a; apparent Vmax was 909 nmoles/h/mg protein in the absence, and 270 in the presence of 4 nmol/l C1a ( Figure S2B ). The discrepancy between erythrocyte and fibroblast Vmax decrease was not explained and may have been due to the use of crude homogenates.
Inhibitor uptake rate by incubated fibroblasts could not be directly measured at low concentrations, since 50 μmol/l is the lower limit for HPLC detection of C1a. Thus, an indirect evaluation of its uptake was used, measuring PNP residual activity in homogenates obtained from control fibroblasts preincubated with complete medium supplied with C1a (5 nmol/l-25 μmol/l) for 180 min. PNP activity decrease was dependent on extracellular concentration of the inhibitor ( Figure S3 ) demonstrating its proportional uptake by cells. C1a concentrations significantly decreasing activity (1 and 25 μmol/l, 30 and 5% residual activity, respectively) were chosen for long time incubation experiments (24, 48, and 72 h).
| Cell viability
The MTT test was performed to check possible toxicity due to d-guanosine nucleotide accumulation. 26 No significant reduction of viable cells was demonstrated in samples of cells from all incubation conditions used, compared with control cells incubated in the identical conditions without added inhibitor. Cell survival ranged 101 ± 5% of controls (mean ± SD) in all the conditions tested.
| Oxipurine excretion by C1a treated fibroblasts
Preliminary studies were conducted in fibroblasts from one control and patient LN1, grown in the presence of increasing concentrations of C1a (0-100 μmol/l) for 24 h. HPLC analysis showed that hypoxanthine and xanthine were mainly represented in the medium of both control and patient cells, with small amounts of inosine and guanosine. Hypoxanthine and xanthine amounts excreted by LN1 fibroblasts were higher than control (Table 1) . Treatment with C1a dramatically decreased excreted hypoxanthine down to undetectable in control and halved it in the patient while increasing inosine and guanosine in both. Small excretions of d-inosine and d-guanosine were observed only at the highest C1a concentrations tested (Table 1) . Similar results (data not shown) were obtained at 48 and 72 h. 27 High amounts of xanthine (16-20 μmol/l) and uric acid (10-14 μmol/l) were found in clean culture medium, which rendered their actual release in extracellular medium difficult to measure. No remarkable modifications in xanthine excretion after C1a treatment was observed (Table 2 ; uric acid data are not shown). These findings, contrasting with the dramatic decrease of hypoxanthine, suggested that XOR may not be expressed or poorly active in human fibroblasts as reported by Simmonds et al. 28 for both fibroblasts and erythrocytes. Moreover, data mining analysis performed to characterize XDH gene expression trends in human tissues and cells, including skin and fibroblasts, revealed that XDH was found abundantly expressed only in hepatocytes and colon mucosa, while a very low level of XDH mRNA was found in skin and in fibroblasts (Tables S2 and S3 ). We confirmed that virtually no XOR activity was detectable in control fibroblast homogenate, compared with high activity in rat liver homogenate assayed as a positive control (unpublished data).
C1a concentrations used for further experiments in cells from four controls and seven patients (LN1, LN2, LN3, LN4, LN6, LN8, LNV5, and LNV7) were 1 and 25 μmol/l. Fibroblasts from all patients released significantly higher amounts of hypoxanthine than controls (+60%, p < 0.01, t test analysis), with no difference between LN and LNV. Higher amounts of xanthine (+29%, p < 0.05, t test analysis) compared to controls were also found (Table 2) , in agreement with other reports. 29 After 24 h incubation with 1 μmol/l C1a, hypoxanthine release was significantly decreased in patients (LNV and LN, p < 0.05) and in controls (p < 0.01); the decrease was more remarkable at 25 μmol/l C1a, with hypoxanthine reaching control basal values in patients (p < 0.01), and virtually undetectable values in controls. Inosine release was increased and very small to undetectable amounts of d-guanosine were found in control and patient cells ( Table 2) . Similar results were obtained at 48 h (data not shown). Inosine up to 20 μmol/l was added to the incubation medium to check the efficacy of the inhibitor at high concentrations of substrate. An excess of plasma inosine concentration, possibly deriving from IMP breakdown and PNP-mediated conversion of hypoxantine excess, was an occasional finding in LND patients (14-50 μmol/l in seven patients, with control 0.1-5; Micheli, unpublished data). After 24 h incubation in the absence of the inhibitor, inosine was converted to hypoxanthine and released in the medium (90% in control and 95% in patient cells). C1a (25 μmol/l) reduced hypoxanthine release to 4% in controls and to 25% in patients (Table 2) . Hypoxanthine decrease expressed as μmol/l equalled inosine increase in all conditions tested, meaning that the amount of inosine which was not converted to hypoxanthine was excreted as such.
| Nucleotides in incubated fibroblasts
Endocellular nucleotide content was analyzed in all experimental conditions. The main nucleotides represented were ADP, GDP, ATP, and GTP; large variability and no significant modifications were found after 24-48 h of incubation with 1 or 25 μmol/l C1a in control or patient fibroblasts (Table 3) 0.96-0.98 in patient cells in all the conditions used, and dGTP was undetectable; small amounts (about 0.1 nmoles/10 6 cells) occurred occasionally at the highest C1a concentration and longer times. Nucleotide pattern was not significantly modified even by inosine addition to culture medium. No nucleosides or free bases were detectable in cell extracts, probably below detection limits. 29 
| DISCUSSION AND CONCLUSIONS
Uric acid hyperproduction in LND patients is one of the lifethreatening traits of this devastating rare disorder, deserving attention to develop appropriate therapeutic strategies. Conventional hypouricemic drugs based on XOR inhibition yield xanthine and hypoxanthine accumulation.
Upstream reduction of purine catabolism and oxypurine production by inhibiting PNP seems an appropriate approach. PNP inhibition by BCX-4208 or Ulodesine (BioCryst Pharmaceuticals) was tested in clinical trials to lower UA in gouty patients not adequately responding to allopurinol. To our knowledge, no preclinical study on the possible therapeutic use of PNP inhibitors to reduce hypoxanthine production upstream has been reported for LND patients.
A new simplified analogue of DADMe-ImmG (C1a) was used in this in vitro study that aimed to ascertain the reliability of this potent PNP inhibitor to develop a safe drug suitable for long-term treatment of LND patients. Synthesis was easy and low-cost, which is fundamental to industrial scale-up.
Significant PNP inhibition was demonstrated in erythrocyte lysates and fibroblast homogenates from both controls and LND/LNV patients at nanomolar concentration of C1a. Micromolar concentrations of the inhibitor remarkably lowered hypoxanthine release in the medium by control and HGPRT-deficient fibroblasts incubated for 24-48 h, with no detectable cell toxicity and occasional trace production of d-guanosine nucleotides. Xanthine was present not only in the extracellular medium of cultured fibroblasts but also in clean culture medium; thus, its excretion was difficult to measure but seemed rather unaffected by any condition used. This may be explained by the fact that XOR is known not to be expressed or very poorly active in human fibroblasts, 28 as confirmed by direct enzymatic assay and by studies on the expression profile of XDH gene in skin and fibroblasts. Oxypurine production in fibroblasts from two patients with some residual GPRT activity and milder neurologic symptoms did not differ from full LND patients. Xanthine toxicity was suggested in LND, 11 but xanthine production is expected to decrease in vivo following PNP inhibition. While we were unable to directly demonstrate this, there was no increase, and the inverse correlation between excreted hypoxantine and inosine under all conditions, including with added inosine, suggests that the amount of inosine not converted to hypoxanthine is excreted. Overall, the major finding is that purine breakdown can be decreased by PNP inhibition in vitro. Further studies would be needed before being certain this approach would be safe in LND, including evaluation of lymphocyte toxicity. The present results encourage further studies on the use of C1a as a therapeutic strategy against uric acid hyperproduction in LND patients.
T A B L E 3 Endocellular nucleotides in fibroblasts (pmoles/10 6 cells, mean ± SD) from controls (n = 4) and patients (LN2, LN4, LN6, LNV5, LNV7) after 24 h incubation with 1 and 25 μmol/l C1a in the presence or absence of 20 μmol/l inosine 
